NCT02885636View on ClinicalTrials.gov

Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Congestive Heart FailureHeart Failure, Left-SidedLeft-Sided Heart Failure
Interventions
DRUG

Albuterol

": Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"

OTHER

Saline placebo

Saline inhaled through a nebulizer as a single dose

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Mayo Clinic

OTHER

NCT02885636 - Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial | Biotech Hunter | Biotech Hunter